Trafalgar International (GCAN) Liabilities and Shareholders Equity (2017 - 2026)
Trafalgar International (GCAN) posted Liabilities and Shareholders Equity of $1439.0 for Q1 2026, up 76.56% on a QoQ basis from $815.0 in Q4 2025, and down 96.89% year-over-year from $46213.0 in Q1 2025.
Analysis
Trafalgar International (GCAN) Liabilities and Shareholders Equity (2017 - 2026) Analysis & Trends
Trafalgar International has reported Liabilities and Shareholders Equity for 10 years, with the latest figure at $1439.0 in Q1 2026.
- On a quarterly basis, Liabilities and Shareholders Equity fell 96.89% year-over-year to $1439.0 in Q1 2026; TTM through Mar 2026 was $50321.0, a 79.97% decrease from a year earlier, with the FY2025 full-year figure at $815.0, down 98.59% from the prior year.
- Liabilities and Shareholders Equity was $1439.0 for Q1 2026 at Trafalgar International, up from $815.0 in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $381756.0 in Q1 2022, with the low at $815.0 in Q4 2025.
- Average Liabilities and Shareholders Equity over 5 years is $153525.2, with a median of $133490.0 recorded in 2024.
- The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity grew 2.45% in 2022, then tumbled 98.59% in 2025.
- Over 5 years, Liabilities and Shareholders Equity stood at $280447.0 in 2022, then sank by 38.57% to $172276.0 in 2023, then plunged by 66.46% to $57785.0 in 2024, then sank by 98.59% to $815.0 in 2025, then soared by 76.56% to $1439.0 in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $1439.0 (Q1 2026), $815.0 (Q4 2025), and $21355.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 201.06 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 122.03 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 201.13 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | 150.01 Bn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | 4.32 Bn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 7.87 Bn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 7.22 Bn |
| 10 | Trafalgar International | 217,335.05 | 217,335.05 | - | 1,439.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 1,439.00 |
| Dec 31, 2025 | 815.00 |
| Sep 30, 2025 | 21,355.00 |
| Jun 30, 2025 | 26,712.00 |
| Mar 31, 2025 | 46,213.00 |
| Dec 31, 2024 | 57,785.00 |
| Sep 30, 2024 | 63,949.00 |
| Jun 30, 2024 | 83,233.00 |
| Mar 31, 2024 | 133,490.00 |
| Dec 31, 2023 | 172,276.00 |
| Sep 30, 2023 | 206,199.00 |
| Jun 30, 2023 | 248,664.00 |
| Mar 31, 2023 | 260,720.00 |
| Dec 31, 2022 | 280,447.00 |
| Sep 30, 2022 | 300,761.00 |
| Jun 30, 2022 | 324,114.00 |
| Mar 31, 2022 | 381,756.00 |
| Dec 31, 2021 | 392,937.00 |
| Sep 30, 2021 | 509,775.00 |
| Jun 30, 2021 | 583,597.00 |